Information Provided By: 
Fly News Breaks for July 23, 2019
DHR
Jul 23, 2019 | 08:45 EDT
Argus analyst David Toung raised his price target on Danaher to $165 and kept his Buy rating after its "strong" Q2 earnings beat along with its raised FY19 EPS guidance reported last week. The analyst cites the company's sales growth in its U.S. and overseas markets and expects its "strong core business" to boost its earnings by double-digits and sales by mid-single-digits.
News For DHR From the Last 2 Days
DHR
Apr 24, 2024 | 09:23 EDT
DHR
Apr 24, 2024 | 07:22 EDT
DHR
Apr 24, 2024 | 06:40 EDT
Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.
DHR
Apr 24, 2024 | 06:32 EDT
DHR
Apr 24, 2024 | 05:28 EDT
Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.
